{
  "zip": "215123",
  "sector": "",
  "fullTimeEmployees": 2673,
  "longBusinessSummary": "Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar for the treatment of metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; IBI-307, an anti-RANKL antibody for metastatic bone tumor; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has a strategic collaboration with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was founded in 2011 and is headquartered in Suzhou, China.",
  "city": "Suzhou",
  "phone": "86 512 6956 6088",
  "country": "China",
  "companyOfficers": [],
  "website": "http://www.innoventbio.com",
  "maxAge": 1,
  "address1": "168 Dongping Street",
  "fax": "86 512 6956 6088",
  "industry": "",
  "address2": "Suzhou Industrial Park",
  "previousClose": 10.5,
  "regularMarketOpen": 11.15,
  "twoHundredDayAverage": 7.457845,
  "trailingAnnualDividendYield": null,
  "payoutRatio": null,
  "volume24Hr": null,
  "regularMarketDayHigh": 10.5,
  "navPrice": null,
  "averageDailyVolume10Day": 3100,
  "totalAssets": null,
  "regularMarketPreviousClose": 10.5,
  "fiftyDayAverage": 8.473838,
  "trailingAnnualDividendRate": null,
  "open": 11.15,
  "averageVolume10days": 3100,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.000632,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 10.5,
  "priceHint": 2,
  "currency": "USD",
  "regularMarketVolume": 3000,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 2205178368,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 7785,
  "priceToSalesTrailing12Months": null,
  "dayLow": 10.5,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 3000,
  "fiftyTwoWeekHigh": 13.5,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 3.4,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 10.5,
  "exchange": "PNK",
  "shortName": "INNOVENT BIOLOGICS INC",
  "longName": "Innovent Biologics, Inc.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "IVBXF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_141109936",
  "uuid": "fb1151f1-0dfb-3372-b4b3-a51de524cbe2",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": -0.95702004,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 210016992,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.38319,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.087390006,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1593475200,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 1097991837,
  "enterpriseValue": 14102819840,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 11.15,
  "logo_url": "https://logo.clearbit.com/innoventbio.com"
}